New insight into targeting the DNA damage response in the treatment of glioblastoma

Abstract

Glioblastoma (GBM) is the most common invasive malignant tumor in human brain tumors, representing the most severe grade of gliomas. Despite existing therapeutic approaches, patient prognosis remains dismal, necessitating the exploration of novel strategies to enhance treatment efficacy and extend survival. Due to the restrictive nature of the blood-brain barrier (BBB), small-molecule inhibitors are prioritized in the treatment of central nervous system tumors. Among these, DNA damage response (DDR) inhibitors have garnered significant attention due to their potent therapeutic potential across various malignancies. This review provides a detailed analysis of DDR pathways as therapeutic targets in GBM, summarizes recent advancements, therapeutic strategies, and ongoing clinical trials, and offers perspectives on future directions in this rapidly evolving field. The goal is to present a comprehensive outlook on the potential of DDR inhibitors in improving GBM management and outcomes.

Keywords

Glioblastoma / DNA damage response / Small molecule inhibitors

References

[1] Wang S, Li X, Hu Y, et al. Discovery of N-alkyl-N-benzyl thiazoles as novel TRPC antagonists for the treatment of glioblastoma multiforme[J]. Eur J Med Chem, 2024, 265: 116066.

[2] Zhang MH, Din YS, Gao MK, et al. Discovery of novel N-(anthracen-9-ylmethyl) benzamide derivatives as ZNF207 inhibitors promising in treating glioma[J]. J Med Chem, 2024, 67(5): 3909-3934.

[3] An RB, Liu LJ, Wei S, et al. Controlling disassembly of paramagnetic prodrug and photosensitizer nanoassemblies for on-demand orthotopic glioma theranostics[J]. ACS Nano, 2022, 16 (12): 20607-20621.

[4] Shergalis A, Bankhead A, Luesakul U, et al. Current challenges and opportunities in treating glioblastoma[J]. Pharmacol Rev, 2018, 70 (3): 412-445.

[5] Zhu NC, Chen SJ, Jin Y, et al. Enhancing glioblastoma immunotherapy with integrated chimeric antigen receptor T cells through the re-education of tumor-associated microglia and macrophages[J]. ACS Nano, 2024, 18 : 11165-11182.

[6] Yang HY, Zhang DY, Yuan ZY, et al. Novel 4-aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent[J]. Eur J Med Chem, 2024, 267 : 116205.

[7] Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis: DNA damage and repair[J]. Environ Mol Mutagen, 2017, 58 (5): 235-263.

[8] Parry EM, Gable DL, Stanley SE, et al. Germline mutations in DNA repair genes in lung adenocarcinoma[J]. J Thorac Oncol, 2017, 12 (11): 1673-1678.

[9] Pearl LH, Schierz AC, Ward SE, et al. Therapeutic opportunities within the DNA damage response[J]. Nat Rev Cancer, 2015, 15 (3): 166-180.

[10] Rodríguez MI, Majuelos-Melguizo J, Martí Martín-Consuegra JM, et al. Deciphering the insights of poly (ADP-ribosylation) in tumor progression[J]. Med Res Rev, 2015, 35( 4): 678-697.

[11] Kunze FA, Hottiger MO. Regulating immunity via ADP-ribosylation: therapeutic implications and beyond[J]. Trends Immunol, 2019, 40 (2): 159-173.

[12] Xu YZ, Wu HH, Huang L, et al. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy[J]. Eur J Med Chem, 2022, 237 : 114417.

[13] Chen SY, Zhang WX, Li X, et al. DNA polymerase beta connects tumorigenicity with the circadian clock in liver cancer through the epigenetic demethylation of Per1[J]. Cell Death Dis, 2024, 15 (1): 1-14.

[14] Schreiber V, Dantzer F, Ame JC, et al. Poly (ADP-ribose): novel functions for an old molecule[J]. Nat Rev Mol Cell Biol, 2006, 7 (7): 517-528.

[15] Oliver AW, Amé J, Roe SM, et al. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase‐ 2 [J]. Nucleic Acids Res, 2004, 32 (2): 456-464.

[16] Ménissier de Murcia J, Ricoul M, Tartier L. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse[J]. EMBO J, 2023, 22 (9): 2255-2263.

[17] Ren JK, Quan X, Liu Y, et al. Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers[J]. Bioorg Med Chem Lett, 2022, 78 : 129046.

[18] Masutani M, Suzuki H, Kamada N, et al. Poly (ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes[J]. Proc Natl Acad Sci USA, 1999, 96 (5): 2301-2304.

[19] de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells[J]. Proc Natl Acad Sci USA, 1997, 94 (14): 7303-7307.

[20] Grundy GJ, Polo LM, Zeng Z, et al. PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2BGlu2[J]. Nat Commun, 2016, 7 (1): 12404.

[21] Wu ZY, Bai Y, Jin JM, et al. Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer[J]. Eur J Med Chem, 2021, 217 : 113357.

[22] Wang JW, He GC, Li H, et al. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer[J]. Eur J Med Chem, 2021, 213 : 113054.

[23] Wang SP, Wu SQ, Huang SH, et al. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair[J]. Cell Death Dis, 2021, 12 (12): 1-12.

[24] Wu SF, Li XL, Gao F, et al. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O⁶-methylguanine DNA damage in glioblastoma[J]. Neuro-Oncology, 2021, 23 (6): 920-931.

[25] Tentori L, Ricci-Vitiani L, Muzi A, et al. Pharmacological inhibition of poly (ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide [J]. BMC Cancer, 2015, 14 : 151.

[26] Higuchi F, Nagashima H, Ning JF, et al. Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficientis is independent of base excision repair[J]. Clin Cancer Res, 2020, 26 (7): 1690-1699.

[27] Halford SER, Cruickshank G, Dunn L, et al. Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM).[J]. J Clin Oncol, 2017, 35 (15_suppl): 2022-2022.

[28] Bisht P, Kumar VU, Pandey R, et al. Role of PARP inhibitors in glioblastoma and perceiving challenges as well as strategies for successful clinical development[J]. Front Pharmacol, 2022, 13 : 939570.

[29] Kizilbash SH, Gupta SK, Chang K, et al. Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of poly (ADP-ribose) polymerase inhibition on temozolomide therapy in glioblastoma[J]. Mol Cancer Ther, 2017, 16 (12): 2735-2746.

[30] Zhang SL, Peng X, Li XF, et al. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair[J]. Cell Death Dis, 2021, 12 (6): 546.

[31] Li Y, Wang YT, Zhang WP, et al. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression[J]. Sci Rep, 2021, 11 (1): 4774.

[32] Jue TR, Nozue K, Lester AJ, et al. Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma[J]. J Transl Med, 2017, 15 : 61.

[33] Ghorai A, Mahaddalkar T, Thorat R, et al. Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence[J]. Cancer Lett, 2020, 490 : 44-53.

[34] Shao JL, Huang L, Lai WW, et al. Design, synthesis, and biological evaluation of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3-related (ATR) kinase for the efficient treatment of cancer[J]. Molecules, 2023, 28 (11): 4521.

[35] Cai BL, Hu ZY, Tang HY, et al. Triptolide impairs genome integrity by directly blocking the enzymatic activity of DNA-PKcs in human cells[J]. Biomed Pharmacother, 2020, 129 : 110427.

[36] Chen X, Xu X, Chen Y, et al. Structure of an activated DNA-PK and its implications for NHEJ[J]. Mol Cell, 2021, 81 (4): 801-810. e3.

[37] Zhao B, Rothenberg E, Ramsden DA, et al. The molecular basis and disease relevance of non-homologous DNA end joining[J]. Nat Rev Mol Cell Biol, 2020, 2 1 (12): 765-781.

[38] Karanam K, Kafri R, Loewer A, et al. Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid-S phase[J]. Mol Cell, 2012, 47 (2): 320-329.

[39] Mao Z, Bozzella M, Seluanov A, et al. Comparison of nonhomologous end joining and homologous recombination in human cells[J]. DNA Repair, 2008, 7 (10): 1765-1771.

[40] Kotula E, Berthault N, Agrario C, et al. DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion[J]. Cell Cycle, 2015, 14 (12): 1961-1972.

[41] Dietlein F, Thelen L, Jokic M, et al. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC[J]. Cancer Discov, 2014, 4 (5): 592-605.

[42] Zhang J, Jing L, Tan SB, et al. Inhibition of miR-1193 leads to synthetic lethality in glioblastoma multiforme cells deficient of DNA-PKcs[J]. Cell Death Dis, 2020, 11 (7): 602.

[43] Dong C, Wang Y, Tu ZL, et al. Recent advances in ATM inhibitors as potential therapeutic agents[J]. Future Med Chem, 2022, 14 (23): 1811-1830.

[44] Jackson SP, Bartek J. The DNA-damage response in human biology and disease[J]. Nature, 2009, 461 (7267): 1071-1078.

[45] Rao QH, Liu MJ, Tian Y, et al. Cryo-EM structure of human ATR-ATRIP complex[J]. Cell Res, 2018, 28 (2): 143-156.

[46] Xiao JX, Liu MJ, Qi YL, et al. Structural insights into the activation of ATM kinase[J]. Cell Res, 2019, 29 (8): 683-685.

[47] Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation[J]. Nature, 2003, 421 (6922): 499-506.

[48] Paull TT. Mechanisms of ATM Activation[J]. Annu Rev Biochem, 2015, 84 (1): 711-738.

[49] Ye L, Liu BB, Huang JL, et al. DCLK1 and its oncogenic functions: a promising therapeutic target for cancers[J]. Life Sci, 2024, 336 : 122294.

[50] Zhang X, Li T, Yang M, et al. Acquired temozolomide resistance in MGMT low gliomas is associated with regulation of homologous recombination repair by ROCK2[J]. Cell Death Dis, 2022, 13 (2): 1-15.

[51] Yazinski SA, Zou L. Functions, regulation, and therapeutic Implications of the ATR checkpoint pathway[J]. Annu Rev Genet, 2016, 50 (1): 155-173.

[52] Zhang MJ, Qu JX, Gao ZW. Timosaponin AIII induces G₂/M arrest and apoptosis in breast cancer by activating the ATM/Chk2 and p38 MAPK signaling pathways[J]. Front Pharmacol, 2021, 11 (15): 601468.

[53] Biddlestone-Thorpe L, Sajjad M, Rosenberg E, et al. ATM kinase inhibition preferentially sensitizes p53 mutant glioma to ionizing radiation[J]. Clin Cancer Res, 2013, 19 (12): 3189-3200.

[54] Durant ST, Zheng L, Wang Y, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models[J]. Sci Adv, 2018, 4 (6): eaat1719.

[55] Chen JJ, Laverty DJ, Talele S, et al. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization[J]. Sci Transl Med, 2024, 16 (734): eadj5962.

[56] Pike KG, Hunt TA, Barlaam B, et al. Identification of novel, selective ataxia-telangiectasia mutated kinase inhibitors with the ability to penetrate the blood-brain barrier: the discovery of AZD1390[J]. J Med Chem, 2024 67 (4): 3090-3111.

[57] Carruthers R, Ahmed SU, Strathdee K, et al. Abrogation of radioresistance in glioblastoma stem‐like cells by inhibition of ATM kinase[J]. Mol Oncol, 2015, 9 (1): 192-203.

[58] Qin T, Mullan B, Ravindran R, et al. ATRX loss in glioma results in dysregulation of cell cycle phase transition and ATM inhibitor radio-sensitization[J]. Cell Rep, 2022, 38 (2): 110216.

[59] Serrano MA, Li Z, Dangeti M, et al. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair[J]. Oncogene, 2013, 32 (19): 2452-2462.

[60] Liu S, Opiyo SO, Manthey K, et al. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress[J]. Nucleic Acids Res, 2012, 40 (21): 10780-10794.

[61] Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer[J]. Pharmacol Therapeut, 2015, 149 : 124-138.

[62] Riabinska A, Daheim M, Herter-Sprie GS, et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors[J]. Sci Transl Med, 2013, 5 (189): 189ra78.

[63] Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome[J]. Nat Rev Mol Cell Biol, 2017, 18 (10): 622-636.

[64] Toledo LI, Altmeyer M, Rask MB, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA[J]. Cell, 2013, 155 (5): 1088-1103.

[65] Sanjiv K, Hagenkort A, Calderón-Montaño JM, et al. Cancer-specific synthetic lethality between ATR and CHK1 kinase activities[J]. Cell Rep, 2016, 14 (2): 298-309.

[66] Duan YX, Cheng HD, Zhuang LL, et al. Discovery of thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase[J]. Eur J Med Chem, 2023, 255 : 115370.

[67] Duan YX, Zhuang LL, Xu YR, et al. Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors[J]. Bioorg Chem, 2023, 136 : 106535.

[68] Kwok M, Davies N, Agathanggelou A, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells[J]. Blood, 2016, 127 (5): 582-595.

[69] Min A, Im SA, Jang HM, et al. AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells[J]. Mol Cancer Ther, 2017, 16 (4): 566-577.

[70] Ning JF, Stanciu M, Humphrey MR, et al. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma[J]. Nat Commun, 2019, 10 : 2910.

[71] Mahajan K, Mahajan NP. WEE1 tyrosine kinase, a novel epigenetic modifier[J]. Trends Genet, 2013, 29 (7): 394-402.

[72] Wang Y, Xu CY, Jiang YQ, et al. Advanced design, synthesis, and evaluation of highly selective Wee1 inhibitors: enhancing pharmacokinetics and antitumor efficacy[J]. J Med Chem, 2024 67 (12): 9927-9949.

[73] Yan JX, Zhuang LL, Wang Y, et al. Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022)[J]. Expert Opin Ther Patents, 2022, 32 (12): 1217-1244.

[74] Aarts M, Sharpe R, Garcia-Murillas I, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1[J]. Cancer Discov, 2012, 2 (6): 524-539.

[75] Bai ZS, Zhou YR, Peng YL, et al. Perspectives and mechanisms for targeting mitotic catastrophe in cancer treatment[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878 (5): 188965.

[76] Chen HY, Yang F, Zhao QY, et al. GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition[J]. J Pharm Pharmacol, 2024, 76 (8): 1006-1007

[77] Toledo CM, Ding Y, Hoellerbauer P, et al. Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in glioblastoma stem-like cells[J]. Cell Rep, 2015, 13 (11): 2425-2439.

[78] Pokorny JL, Calligaris D, Gupta SK, et al. The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma[J]. Clin Cancer Res, 2015, 21 (8): 1916-1924.

[79] Wu SF, Wang SZ, Gao F, et al. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma[J]. Neuro Oncol, 2018, 20 (1): 78-91.

[80] Clausse V, Goloudina AR, Uyanik B, et al. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy[J]. Cell Death Dis, 2016, 7 (4): e2195-e2195.

[81] Tong C, Chang XJ, Qu FG, et al. Overview of the development of protein arginine methyltransferase modulators: achievements and future directions[J]. Eur J Med Chem, 2024, 267 : 116212.

[82] Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation[J]. Nat Rev Mol Cell Biol, 2019, 20 (10): 642-657.

[83] Blanc RS, Richard S. Arginine methylation: the coming of age[J]. Mol Cell, 2017, 65 (1): 8-24.

[84] Jarrold J, Davies CC. PRMTs and arginine methylation: cancer’s best-kept secret?[J]. Trends Mol Med, 2019, 25 (11): 993-1009.

[85] Wu Q, Schapira M, Arrowsmith CH, et al. Protein arginine methylation: from enigmatic functions to therapeutic targeting[J]. Nat Rev Drug Discov, 2021, 20 (7): 509-530.

[86] Kim H, Kim H, Feng Y, et al. PRMT5 control of cGAS/ STING and NLRC5 pathways defines melanoma response to antitumor immunity[J]. Sci Transl Med, 2020, 12 (551): eaaz5683.

[87] Yan FT, Alinari L, Lustberg ME, et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma[J]. Cancer Res, 2014, 74 (6): 1752-1765.

[88] Hu D, Gur M, Zhou Z, et al. Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis[J]. Nat Commun, 2015, 6 (1): 8419.

[89] Chiang K, Zielinska AE, Shaaban AM, et al. PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression[J]. Cell Rep, 2017, 21 (12): 3498-3513.

[90] Migliori V, Müller J, Phalke S, et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance[J]. Nat Struct Mol Biol, 2012, 19 (2): 136-144.

[91] Karkhanis V, Hu YJ, Baiocchi RA, et al. Versatility of PRMT5-induced methylation in growth control and development[J]. Trends Biochem Sci, 2011, 36 (12): 633-641.

[92] Hsu JM, Chen CT, Chou CK, et al. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation[J]. Nat Cell Biol, 2011, 13 (2): 174-181.

[93] He W, Ma XY, Yang X, et al. A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage[J]. Nucleic Acids Res, 2011, 39 (11): 4719-4727.

[94] Guo ZG, Zheng LZ, Xu HF, et al. Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding[J]. Nat Chem Biol, 2010, 6 (10): 766-773.

[95] Clarke TL, Sanchez-Bailon MP, Chiang K, et al. PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination[J]. Mol Cell, 2017, 65 (5): 900-916. e7.

[96] Rehman I, Basu SM, Das SK, et al. PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes[J]. Nucleic Acids Res, 2018, 46 (11): 5601-5617.

[97] Hamard PJ, Santiago GE, Liu F, et al. PRMT5 regulates DNA repair by controlling the alternative splicing of key histone-modifying enzymes[J]. Cell Rep, 2018, 24 (10): 2643-2657.

[98] Bajbouj K, Ramakrishnan R, Ihmaid AMH, et al. Abstract 4711: PRMT5 selective inhibitor enhances therapeutic efficacy of cisplatin in lung adenocarcinoma cells[J]. Cancer Res, 2019, 79 (13_Supplement): 4711.

[99] Mavrakis KJ, McDonald ER, Schlabach MR, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5[J]. Science, 2016, 351 (6278): 1208-1213.

[100] Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells[J]. Science, 2016, 351 (6278): 1214-1218.

[101] Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/ PRMT5/RIOK1 axis[J]. Cell Rep, 2016, 15 (3): 574-587.

[102] Banasavadi-Siddegowda YK, Russell L, Frair E, et al. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells[J]. Oncogene, 2017, 36 (2): 263-274.

[103] Banasavadi-Siddegowda YK, Welker AM, An M, et al. PRMT5 as a druggable target for glioblastoma therapy[J]. Neuro Oncol, 2018, 20 (6): 753-763.

[104] Sachamitr P, Ho JC, Ciamponi FE, et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma[J]. Nat Commun, 2021, 12 (1): 979.

[105] Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase[J]. Nat Rev Mol Cell Biol, 2004, 5 (10): 792-804.

[106] Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25[J]. Science, 1997, 277 (5331): 1497-1501.

[107] Narayanaswamy PB, Tkachuk S, Haller H, et al. CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling[J]. Cell Death Dis, 2016, 7 (9): e2383.

[108] Wang MN, Chen SY, Ao DY. Targeting DNA repair pathway in cancer: mechanisms and clinical application[J]. MedComm, 2021, 2(4): 654-691.

[109] Urist M, Tanaka T, Poyurovsky MV, et al. p 73 Induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2[J]. Genes Dev, 2004, 18 (24): 3041-3054.

[110] Sidi S, Sanda T, Kennedy RD, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and Caspase-3[J]. Cell, 2008, 133 (5): 864-877.

[111] Bao SD, Wu QL, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response[J]. Nature, 2006, 444 (7120): 756-760.

[112] Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models[J]. J Clin Invest, 2012, 122 (4): 1541-1552.

[113] Signore M, Pelacchi F, di Martino S, et al. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo[J]. Cell Death Dis, 2014 5 (5): e1223.

[114] Corrales-Guerrero S, Cui T, Castro-Aceituno V, et al. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1[J]. Cancer Lett, 2023, 570 : 216308.

[115] Parmar K, Kochupurakkal BS, Lazaro JB, et al. The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition[J]. Clin Cancer Res, 2019, 25 (20): 6127-6140.

[116] Lim DS, Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53[J] Mol Cell Biol, 1996, 16 (12): 7133-7143.

[117] Reymer A, Frykholm K, Morimatsu K, et al. Structure of human Rad51 protein filament from molecular modeling and site-specific linear dichroism spectroscopy[J]. Proc Natl Acad Sci USA, 2009, 106 (32): 13248-13253.

[118] Demeyer A, Benhelli-Mokrani H, Chénais B, et al. Inhibiting homologous recombination by targeting RAD51 protein[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876 (2): 188597.

[119] Bonilla B, Hengel SR, Grundy MK, et al. RAD51 gene family structure and function[J]. Annu Rev Genet, 2020, 54 (1): 25-46.

[120] Thacker J. The RAD51 gene family, genetic instability and cancer[J]. Cancer Lett, 2005, 219 (2): 125-135.

[121] Richardson C. RAD51, genomic stability, and tumorigenesis[J]. Cancer Lett, 2005, 218 (2): 127-139.

[122] Hine CM, Seluanov A, Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy[J]. Proc Natl Acad Sci USA, 2008, 105 (2): 20810-20815.

[123] Wu SQ, Huang SH, Lin QW, et al. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways[J]. Pharmacol Res, 2022, 175 : 106040.

[124] Zhao M, Wang DD, Che Y, et al. Ginsenosides synergize with mitomycin C in combating human non-small cell lung cancer by repressing Rad51-mediated DNA repair[J]. Acta Pharmacol Sin, 2018, 39(3): 449-458.

[125] Welsh JW, Ellsworth RK, Kumar R, et al. Rad51 protein expression and survival in patients with glioblastoma multiforme[J]. Int J Radiat Oncol Biol Phys, 2009, 74 (4): 1251-1255.

[126] Ward A, Khanna KK, Wiegmans AP. Wiegmans, Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51[J]. Cancer Treat Rev, 2015, 41(1): 35-45.

[127] Gachechiladze M, Škarda J, Soltermann A, et al. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies[J]. Int J Cancer, 2017, 141 (7): 1286-1294.

[128] Zhang N, Wu XJ, Yang LX, et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA repair gene Rad51[J]. Clin Cancer Res, 2012, 18 (21): 5961-5971.

[129] Liu H, Qiu WM, Sun TY, et al. Therapeutic strategies of glioblastoma (GBM): the current advances in the molecular targets and bioactive small molecule compounds[J]. Acta Pharm Sin B, 2022, 12 (4): 1781-1804.

[130] Peng X, Wang YY, Zhang SL, et al. Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair[J]. Signal Transduct Target Ther, 2023, 8 (1): 119.

[131] Peng X, Zhang SL, Wang YY, et al. Stellettin B sensitizes glioblastoma to DNA-damaging treatments by suppressing PI3K-mediated homologous recombination repair[J]. Adv Sci, 2022, 10 : 2205529.

[132] Chang KF, Huang XF, Chang JT, et al, Cedrol, a sesquiterpene alcohol, enhances the anticancer efficacy of temozolomide in attenuating drug resistance via regulation of the DNA damage response and MGMT expression[J]. J Nat Prod, 2020, 83 (10): 3021-3029.

[133] Lim YC, Ensbey KS, Offenhäuser C, et al. Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore[J]. Neuro Oncol, 2020, 22 (2): 216-228.

[134] Qiu RZ, Zhang JJ, Ge C, et al. Ginsenosides Rg1 and CK control temozolomide resistance in glioblastoma cells by modulating cholesterol efflux and lipid raft distribution[J]. Evid-Based Compl Alt, 2022, 2022 : 1897508.

[135] Zhang WB, Wang Z, Shu F, et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition[J]. J Biol Chem, 2010, 285 (52): 40461-40471.

[136] Zhang X, Liu XT, Zhou W, et al. Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2[J]. Cell Death Dis, 2018, 9 (2): 190.

[137] Ding YX, Zhou Y, Li ZH, et al. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP3R1/AKT/β-catenin pathway[J]. Life Sci, 2020, 260 : 118411.

[138] Wei M, Ma R, Huang SL, et al. Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia[J]. J Cell Physiol, 2019, 234(10): 17392-17404.

[139] Semukunzi H, Roy D, Li HY, et al. IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α[J]. Biomed Pharmacother, 2017, 89 : 805-811.

[140] Qiang L, Wu T, Zhang HW, et al. HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway[J]. Cell Death Differ, 2012, 19 (2): 284.

[141] Zhao C, Wang HY, Xiong CH, et al. Hypoxic glioblastoma release exosomal VEGF-A induce the permeability of blood-brain barrier[J]. Biochem Biophys Res Commun, 2018, 502(3): 324-331.

[142] Zhu Y, Sun JM, Sun ZC, et al. MLK3 is associated with poor prognosis in patients with glioblastomas and actin cytoskeleton remodeling in glioblastoma cells[J]. Front Oncol, 2021, 10 : 600762.

[143] Li YX, Wang TP, Wan Q, et al. TRAF4 maintains deubiquitination of caveolin-1 to drive glioblastoma stemness and temozolomide resistance[J]. Cancer Res, 2022, 82(19): 3573-3587.

[144] Qin HK, Gui YP, Ma R, et al. miR-1258 Attenuates tumorigenesis through targeting E2F1 to inhibit PCNA and MMP2 transcription in glioblastoma[J]. Front Oncol, 2021, 11 : 671144.

[145] Yuan DY, Chen WT, Jin SS, et al. Co-expression of immune checkpoints in glioblastoma revealed by single-nucleus RNA sequencing and spatial transcriptomics[J]. Comput Struct Biotechnol J, 2024, 23 : 1534-1546.

[146] Sun JM, Fan HY, Zhu Y, et al. Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration[J]. Life Sci Alliance, 2023, 6 (12): e202301966.

[147] Yu LN, Jin Y, Song MJ, et al. When natural compounds meet nanotechnology: nature-inspired nanomedicines for cancer immunotherapy[J]. Pharmaceutics, 2022, 14 (8): 1589.

[148] Sun CM, Ding Y, Zhou L, et al. Noninvasive nanoparticle strategies for brain tumor targeting[J]. Nanomed-Nanotechnol, 2017, 13 (8): 2605-2621.

[149] Hao MX, Hou SY, Li WS, et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy[J]. Sci Transl Med, 2020, 12 (571): eaaz6667.

[150] Gherardini L, Vetri Buratti V, Maturi M, et al. Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models[J]. Sci Rep, 2023, 13 (1): 4630.

[151] Ortiz R, Perazzoli G, Cabeza L, et al. Temozolomide: an updated overview of resistance mechanisms nanotechnology advances and clinical applications[J]. Curr Neuropharmacol, 2021, 19 (4): 513-537.

[152] Ma YY, Zhang JN, Rui YL, et al. Depletion of glioma stem cells by synergistic inhibition of mTOR and c-Myc with a biological camouflaged cascade brain-targeting[J]. Biomaterials, 2021, 268: 120564.

[153] Yu F, Asghar S, Zhang M, et al. Local strategies and delivery systems for the treatment of malignant gliomas[J]. J Drug Target, 2017, 27 (4): 367-378.

[154] Song MM, Tian JM, Wang L, et al. Efficient delivery of lomitapide using hybrid membrane-coated tetrahedral DNA nanostructures for glioblastoma therapy[J]. Adv Mater, 2024, 36 (24): 2311760.

[155] Torres ID, Loureiro JA, Coelho MAN, et al. Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance[J]. Expert Opin Drug Del, 2022, 19 (11): 1397-1415.

[156] Xu Q, Zhang H, Liu HH, et al. Inhibiting autophagy flux and DNA repair of tumor cells to boost radiotherapy of orthotopic glioblastoma[J]. Biomaterials, 2022, 280: 121287.

[157] Lee JA, Ayat N, Sun ZH, et al. Camphausen, improving radiation response in glioblastoma using ECO/siRNA nanoparticles targeting DNA damage repair[J]. Cancers, 2020, 12(11): 3260.

[158] Wang K, Kievit FM, Chiarelli PA, et al. siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model[J]. Adv Funct Mater, 2021, 31 (6): 2007166.

[159] Staniszewska AD, Pilger D, Gill SJ, et al. Preclinical characterization of AZD9574, a blood-brain barrier penetrant inhibitor of PARP1[J]. Clin Cancer Res, 2024, 30 (7):1338-1351.

[160] Johannes JW, Balazs A, Barratt D, et al. Discovery of 5-{4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl] piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): a PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs[J]. J Med Chem, 2021, 64 : 14498-14512.

[161] Bradbury A, Hall S, Curtin N, et al. Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations?[J]. Pharmacol Therapeut, 2020, 207 : 107450.

[162] Rahman R, Trippa L, Lee EQ, et al. Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using bayesian adaptive randomization[J]. J Clin Oncol, 2023, 41(36): 5524-5535.

Funding

National Natural Science Foundation of China(82173652)

Natural Science Foundation of Jiangsu Province(BK20191411)

Natural Science Foundation of Jiangsu Province(BK20221522)

Jiangsu “333 High Level Talents Cultivation” Leading Talents(2022-3-16-203)

Qing Lan Project to SUN Haopeng.